Sedgefield, UK. September 2013 – Specialist 3D cell culture company Reinnervate Ltd today announced that it is entering into a collaboration with leading stem cell company Roslin Cellab to develop 3D stem cell printing products and services using Alvetex® technology.
The two companies will pool their expertise in the areas of 3D cell culture and stem cell biology to bring next generation stem cell products and services to the market. Reinnervate will contribute new Alvetex 3D cell culture variants and expertise while Roslin Cellab will harness its capabilities in the area of stem cell culture and cell printing.
“We are delighted to deepen our links with Reinnervate by working together in this area,” commented Dr. Jason King, Business Development Manager at Roslin Cellab. “This work builds on our earlier collaboration on the 3D culture and differentiation of stem cells using Alvetex,” he added.
Richard Rowling, Commercial Director of Reinnervate Ltd said, “We are very pleased that Roslin Cellab has once again picked Alvetex technology as one of the most appropriate and flexible solutions for 3D cell culture for this new venture. The simple workflow and flexibility of Alvetex products make them an excellent companion for 3D cell printing projects.”
For further information please contact email@example.com
About Reinnervate Ltd
Reinnervate is an innovative life sciences company dedicated to making routine 3D cell culture a reality for researchers in academia and in the pharmaceutical and related industries.
Reinnervate develops, manufactures and sells products for 3D cell culture. During 2013 Reinnervate has launched several new formats including 24 and 96 well plates and developed specialist applications for scientists working in the fields of cancer research, cell migration/invasion and stem cell culture/expansion.
Reinnervate was founded in 2002 based on the pioneering research of Professor Stefan Przyborski and his lab at Durham University, UK, and is funded by NorthStar Equity Investors (NSEI), management and private investors.
About Alvetex® Scaffold
Alvetex® Scaffold is a unique polystyrene material that provides a robust and inert scaffold for cells to grow and form complex 3D structures in vitro, mimicking the normal growth and formation of tissues in the body. Reinnervate has extensively tested and validated Alvetex® Scaffold with a large number of cell types, including liver, skin, cancer and stem cells, all of which have important applications in basic research into cell development, disease modelling and drug safety screening.
Alvetex® Scaffold has been launched globally in several formats: a 12-well culture plate, 24-well culture plate, 96 well plate, 6-well and 12-well inserts. These formats enable scientists to construct different 3D cell culture models and assays. These include screening of novel drugs / drug combinations on 3D culture and co-culture models, co-culture to study cell-cell or cell-matrix interactions, the growth of cells at the air-liquid interface and the long-term culture of cells.
Alvetex® Scaffold was voted as one of the top 100 innovative products of 2011 at the R&D 100 awards and was named among the winners of The Scientist magazine’s “Top 10 Life Science Innovations of 2010.”
Note: Reinnervate Ltd (County Durham, England) was acquired by REPROCELL Inc (Yokohama, Japan) in August 2014. Biopta Ltd (Glasgow, Scotland) was acquired by REPROCELL in November 2015. REPROCELL Europe Ltd was established by merging Reinnervate and Biopta in June 2016.